Alexion Must Face Claims Of Stalling On Drug After Merger
A Delaware Chancery judge has ruled that former shareholders of a biopharmaceutical business acquired by Alexion Pharmaceuticals Inc. can continue going after the company for allegedly failing to make appropriate efforts...To view the full article, register now.
Already a subscriber? Click here to view full article